| I-039 Anne Brochot Comparison of common methodologies for accounting for IIV for oral bioavailability in the absence of intravenous data Wednesday 10:20-11:50 |
| II-021 Yuchen Guo pmxcopula - R package for copula-based covariate simulation Wednesday 15:20-16:50 |
| II-034 Emilie Hénin Population pharmacokinetics of MLT103 and determination of CYP2D6 polymorphism by mixture modelling Wednesday 15:20-16:50 |
| III-014 Lara Marques Toward Personalized Salbutamol Therapy: Validating Virtual Patient-Derived Population Pharmacokinetic Model with Real-World Data Thursday 09:50-11:20 |
| III-073 Morgane PHILIPP Extension of the covariate clinical relevance determination in population pharmacokinetic analyses to the Least Absolute Shrinkage and Selection Operator (LASSO) and to Genetic Algorithm (GA) approaches Thursday 09:50-11:20 |
| III-090 Mar Ribera Armengol Causal considerations in Exposure-Response and Population PK covariate analysis Thursday 09:50-11:20 |
